DAFTAR PUSTAKA

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy [10]. *J Thromb Haemost*. 2007;5(3):632-634. doi:10.1111/j.1538-7836.2007.02374.x
2. National Institute for Health and Care Exellence. Venous thromboembolism in adults: diagnosis and management. *NICE Qual Stand [QS29]*. 2016;(March 2013). www.nice.org.uk/guidance/qs29
3. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. *Blood*. 2017;130(13):1499-1506. doi:10.1182/blood-2017-03-743211
4. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. *Blood*. 2013;122(10):1712-1723. doi:10.1182/blood-2013-04-460121
5. Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. *J Clin Oncol*. 2012;30(31):3870-3875. doi:10.1200/JCO.2011.40.1810
6. Trinh VQ, Karakiewicz PI, Sammon J, et al. Venous thromboembolism after major cancer surgery: Temporal trends and patterns of care. *JAMA Surg*. 2014;149(1):43-49. doi:10.1001/jamasurg.2013.3172
7. Siegal DM, Eikelboom JW, Lee SF, et al. Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. *Cardiovasc Res*. 2020;(167). doi:10.1093/cvr/cvaa044
8. Nicholson M, Chan N, Bhagirath V, Ginsberg J. Prevention of Venous Thromboembolism in 2020 and Beyond. *J Clin Med*. 2020;9(8):2467. doi:10.3390/jcm9082467
9. Lee LH, Gallus A, Jindal R, Wang C, Wu CC. Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review. *Thromb Haemost*. 2017;117(12):2243-2260. doi:10.1160/TH17-02-0134
10. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: Results from the copenhagen city heart study. *Circulation*. 2010;121(17):1896-1903. doi:10.1161/CIRCULATIONAHA.109.921460
11. Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. *Haematologica*. 2019;104(6):1277-1287. doi:10.3324/haematol.2018.209114
12. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. *Cancer*. 2013;119(3):648-655. doi:10.1002/cncr.27772

13. Suharti C, Pangarso EA, Setiawan B, Samakto B De. P-Selectin as Predictor Venous Thromboembolism in Cancer Patients P-Selectin as Predictor Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy. 2019;(September).

14. Gorp ECM Van, Suharti C, Cate H, Dolmans WM V, Meer JWM Van Der. Review : Infectious Diseases and Coagulation Disorders. *J Infect Dis*. 1999;180:176-186.

15. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. *Thromb Res*. 2006;118(5):555-568. doi:10.1016/j.thromres.2005.10.015

16. McCaskill-Stevens W, Wilson J, Bryant J, et al. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. *J Natl Cancer Inst*. 2004;96(23):1762-1769. doi:10.1093/jnci/djh321

17. Schlossman R, Ghobrial I, Lockridge L, Warren D. Dexamethasone : an Observational Study. 2014;160(3):351-358. doi:10.1111/bjh.12152.Endothelial

18. Kirwan CC, Mccollum CN, Mcdowell G, Byrne GJ. Investigation of Proposed Mechanisms of Chemotherapy-Induced Venous Thromboembolism: Endothelial Cell Activation and Procoagulant Release Due to Apoptosis. *Clin Appl Thromb*. 2015;21(5):420-427. doi:10.1177/1076029615575071

19. Budnik I, Brill A. Immune Factors in Deep Vein Thrombosis Initiation. *Trends Immunol*. 2018;39(8):610-623. doi:10.1016/j.it.2018.04.010

20. Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. *Front Pediatr*. 2018;6(May). doi:10.3389/fped.2018.00142

21. Kanz R, Vukovich T, Vormittag R, et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. *J Thromb Haemost*. 2011;9(1):57-63. doi:10.1111/j.1538-7836.2010.04069.x

22. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Front Immunol*. 2018;9(APR):1-11. doi:10.3389/fimmu.2018.00754

23. Manly DA, Boles J, MacKman N. Role of tissue factor in venous thrombosis. *Annu Rev Physiol*. 2011;73:515-525. doi:10.1146/annurev-physiol-042210-121137

24. Kalayci A, Gibson CM, Chi G, et al. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. *Thromb Haemost*. 2018;118(12):2046-2052. doi:10.1055/s-0038-1675606

25. Fernandes CJ, Morinaga LTK, Alves JL, et al. Cancer-associated thrombosis: The when, how and why. *Eur Respir Rev*. 2019;28(151):1-11. doi:10.1183/16000617.0119-2018

26. Noble S, J Pasi. Epidemiology and pathophysiology of cancer-associated

thrombosis. *Br J Cancer*. 2010;102(1):S2-S9. doi:10.1038/sj.bjc.6603600

27. Kurniawan LB, Arif M. Hemostasis Berlandaskan Sel Hidup (in Vivo). *Indones J Clin Pathol Med Lab*. 2016;19(3):204. doi:10.24293/ijcpml.v19i3.421

28. Riddel JP, Aouizerat BE, Miaskowski C, Lillicrap DP. Theories of Blood Coagulation. *J Pediatr Oncol Nurs*. 2007;24(3):123-131. doi:10.1177/1043454206298693

29. Ruseva AL, Dimitrova AA. A new understanding of the coagulation process-the cell-based model. *J Biomed Clin Res*. 2011;4(1):17-22.

30. Smith SA. The cell-based model of coagulation: State-Of-The-Art Review. *J Vet Emerg Crit Care*. 2009;19(1):3-10. doi:10.1111/j.1476-4431.2009.00389.x

31. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. *Proc Natl Acad Sci*. 1977;74:5260-5264.

32. Hilden I, Lauritzen B, Sorensen BB. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. *Blood2*. 2012;119:5871-5878.

33. Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. *Science (80-)*. 1991;253:909-912.

34. Nemerson Y. The tissue factor pathway of blood coagulation. *Semin Hematol*. 1992;29:170-176.

35. Bos MHA, van 't Veer C, Reitsma PH. Molecular biology and biochemistry of the coagulation factors and pathway of hemostasis. In: Kaushansky K, Prchal JT, Press OW, et al., eds. *Williams Hematology*. 0th ed. McGraw-Hill Education; 2016.

36. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. *Proc Natl Acad Sci*. 2006;103:3106-3111.

37. Esmon CT. The protein C pathway. *Chest*. 2003;124(Suppl 3):26S-32S.

38. Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibiton of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. *Biochem J*. 1981;193:395-400.

39. Han X, Fiehler R, Broze GJ. Characterization of the protein Z-dependent protease inhibitor. *Blood*. 2000;96(3049-3055).

40. Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. *Thromb Res*. 2013;131(1):24-30. doi:10.1016/j.thromres.2012.10.007

41. Vormittag R, Simanek R, Ay C, et al. High factor VIII levels independently

predict venous thromboembolism in cancer patients: The cancer and thrombosis study. *Arterioscler Thromb Vasc Biol*. 2009;29(12):2176-2181. doi:10.1161/ATVBAHA.109.190827

42. Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. *Cancers (Basel)*. 2018;10(10):1-21. doi:10.3390/cancers10100380

43. Khorana AA. Cancer and Coagulation Alok. *Bone*. 2014;23(1):1-7. doi:10.1002/ajh.23143.Cancer

44. Kumar DR, Hanlin ER, Glurich I, Mazza JJ, Yale SH. Virchow's contribution to the understanding of thrombosis and cellular biology. *Clin Med Res*. 2010;8(3-4):168-172. doi:10.3121/cmr.2009.866

45. De Cicco M. The prothrombotic state in cancer: Pathogenic mechanisms. *Crit Rev Oncol Hematol*. 2004;50(3):187-196. doi:10.1016/j.critrevonc.2003.10.003

46. Petterson TM, O'Fallon WM, Heit JA, Melton LJ, Mohr DN, Silverstein MD. Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism. *Arch Intern Med*. 2003;160(6):809. doi:10.1001/archinte.160.6.809

47. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. *Cancer*. 1984;54(7):1264-1268. doi:10.1002/1097-0142(19841001)54:7<1264::AID-CNCR2820540706>3.0.CO;2-R

48. Expl N, West MS. Chemotherapy e n h a n c e s endothelial cell reactivity to platelets. 1990;8(6).

49. Mills PJ, Parker B, Jones V, et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. *Clin Cancer Res*. 2004;10(15):4998-5003. doi:10.1158/1078-0432.CCR-0734-04

50. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. *J Clin Oncol*. 2002;20(21):4319-4323. doi:10.1200/JCO.2002.02.116

51. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. *Blood*. 2001;98(5):1614-1615. doi:10.1182/blood.V98.5.1614

52. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. *Br J Haematol*. 2004;126(5):715-721. doi:10.1111/j.1365-2141.2004.05078.x

53. Lee WR, Sanda MG, McLaughlin PW. Quality of life after prostate cancer treatment [1] (multiple letters). *J Clin Oncol*. 2002;20(13):3038-3039.

doi:10.1200/JCO.2002.20.13.3038

54. Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. *Br J Haematol*. 2001;115(2):382-391. doi:10.1046/j.1365-2141.2001.03095.x

55. Boccaccio C, Paolo M. Comoglio. Oncogenesis, Cancer and Hemostasis. In: Khorana AA, Francis CW, eds. *Cancer-Associated Thrombosis*. Informa Healthcare USA, Inc; 2008:1-15.

56. Chen L, Deng H, Cui H, Fang J, Zuo Z. Inflammatory responses and inflammation-associated diseases in organs. *Ontarget*. 2018;9(6):7204-7218.

57. Karin M. NF- k B as a Critical Link Between Inflammation and Cancer. Published online 2009:1-15.

58. Aggarwal BB. Nuclear factor- κ B : The enemy within. 2004;6(September):203-208.

59. Diseases I, Approaches TT. Roles of NF- κ B in Cancer and Inflammatory Diseases and Their Therapeutic Approaches. Published online 2016. doi:10.3390/cells5020015

60. Xia Y. NFKB, an active player in human cancer. 2015;2(9):823-830. doi:10.1158/2326-6066.CIR-14-0112.NF-

61. Liu T, Zhang L, Joo D, Sun S. NF- κ B signaling in in fl ammation. *Signal Transduct Target Ther*. 2017;2:e17023. doi:10.1038/sigtrans.2017.23

62. Saghazadeh A, Ha S, Rezaei N. Inflammation in venous thromboembolism : Cause or consequence ? *Int Immunopharmacol*. 2015;28:655-665. doi:10.1016/j.intimp.2015.07.044

63. Granger DN, Senchenkova E. *Inflammation and the Microcirculatin*. Morgan & Claypool Life Sciences; 2010.

64. Mo J, Zhang D, Yang R. Expression of P-selectin , VCAM-1 , and PSGL-1 in traumatic deep venous thrombosis. *Int J Clin Exp Pathol*. 2016;9(3):3403-3409.

65. Tafani M, Pucci B, Russo A, et al. Modulators of HIF1 α and NFkB in cancer treatment : is it a rational approach for controlling malignant progression ? *Front Pharmacol*. 2013;4:1-12. doi:10.3389/fphar.2013.00013

66. Hassan SA, Palaskas N, Kim P, et al. Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis. *Curr Atheroscler Rep*. 2018;20(2). doi:10.1007/s11883-018-0702-5

67. Gara E, Csikó KG, Ruzsa Z, Földes G, Merkely B. Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment. *Med Oncol*. 2019;36(8):1-8. doi:10.1007/s12032-019-1295-8

68. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: Risk of thrombotic complications in L'Asparaginase- induced antithrombin III deficiency. *Blood*. 1994;83(2):386-391.

doi:10.1182/blood.v83.2.386.386

69. Otten HMMB, Mathijssen J, Ten Cate H, et al. Symptomatic Venous Thromboembolism in Cancer Patients Treated with Chemotherapy: An Underestimated Phenomenon. *Arch Intern Med*. 2004;164(2):190-194. doi:10.1001/archinte.164.2.190

70. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. *Cancer*. 1989;63(7):1303-1307. doi:10.1002/1097-0142(19890401)63:7<1303::AID-CNCR2820630713>3.0.CO;2-F

71. Coughlin SR. Thrombin signalling and protease-activated receptors. *Nature*. 2000;407(6801):258-264. doi:10.1038/35025229

72. Abdullah WZ, Roshan TM, Hussin A, Zain WSWM, Abdullah D. Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin. *Blood Coagul Fibrinolysis*. 2013;24(8):893-895. doi:10.1097/MBC.0b013e3283642ee2

73. Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. *Am J Med*. 1990;89(1):25-28. doi:10.1016/0002-9343(90)90093-S

74. Walko CM, Lindley C. Capecitabine: A review. *Clin Ther*. 2005;27(1):23-44. doi:10.1016/j.clinthera.2005.01.005

75. Czaykowski PM. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. *J Urol*. 1998;160(6 I):2021-2024. doi:10.1016/s0022-5347(01)62232-8

76. Cameron AC, Touyz RM, Lang NN. Vascular Complications of Cancer Chemotherapy. *Can J Cardiol*. 2016;32(7):852-862. doi:10.1016/j.cjca.2015.12.023

77. Yu J, Li D, Lei D, et al. Tumor-Specific d-Dimer concentration ranges and influencing factors: A cross-Sectional study. *PLoS One*. 2016;11(11):1-12. doi:10.1371/journal.pone.0165390

78. Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients. *Haematologica*. 2012;97(8):1158-1164. doi:10.3324/haematol.2011.054718

79. Oppelt P, Betbadal A, Nayak L. Approach to chemotherapy-associated thrombosis. *Vasc Med (United Kingdom)*. 2015;20(2):153-161. doi:10.1177/1358863X14568705

80. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. *Br J Cancer*. 2005;93:S23-S27. doi:10.1038/sj.bjc.6602692

81. Franco AT, Corken A, Ware J. Review Article Platelets at the interface of thrombosis , in fl ammation , and cancer. 2016;126(5):582-589. doi:10.1182/blood-2014-08-531582.582

82. Tomimaru Y, Yano M, Takachi K, et al. Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. *J Am Coll Surg*. 2006;202(1):139-145. doi:10.1016/j.jamcollsurg.2005.08.008

83. Palareti G, Cosmi B, Legnani C, et al. d -Dimer Testing to Determine the Duration of Anticoagulation Therapy . *N Engl J Med*. 2006;355(17):1780-1789. doi:10.1056/nejmoa054444

84. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. *Acta Oncol (Madr)*. 2010;49(3):287-297. doi:10.3109/02841860903524396

85. Boucharaba A, Serre CM, Grès S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. *J Clin Invest*. 2004;114(12):1714-1725. doi:10.1172/JCI200422123

86. Cancer Research UK. Your chemotherapy plan.

87. Chen L, Deng H, Cui H, et al. Oncotarget 7204 www.impactjournals.com/oncotarget Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*. 2018;9(6):7204-7218.

88. Starkweather A. Increased Interleukin-6 Activity Associated with Painful Chemotherapy-Induced Peripheral Neuropathy in Women after Breast Cancer Treatment. *Nurs Res Pract*. 2010;2010:1-9. doi:10.1155/2010/281531

89. Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. *Onco Targets Ther*. 2014;7:1015-1023. doi:10.2147/OTT.S60114

90. LG M, JM H, PA V, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. *Am J Pediatr Hematol Oncol*. 16(2):120-126.

91. Cunningham D, Starling N, Rao S, et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. *N Engl J Med*. 2008;358(1):36-46. doi:10.1056/nejmoa073149

92. Pabinger I, Thaler J, Ay C, Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. *Blood*. 2013;122(12):2011-2018. doi:10.1182/blood-2013-04-460147

93. Schaefer JK, Jacobs B, Wakefield TW, Sood SL. New biomarkers and imaging approaches for the diagnosis of deep venous thrombosis. *Curr Opin Hematol*. 2017;24(3):274-281. doi:10.1097/MOH.0000000000000339

94. Gibson NS, Sohne M, Gerdes VEA, Meijers JCM, Buller HR. Clinical usefulness of prothrombin fragment 1 + 2 in patients with suspected pulmonary embolism. *Thromb Res*. 2010;125(1):97-99. doi:10.1016/j.thromres.2009.03.002

95. Barnes DM, Wakefield TW, Rectenwald JE. Novel Biomarkers Associated with Deep Venous Thrombosis: A Comprehensive Review. *Biomark Insights*. 2008;3(734):93-100. doi:10.4137/BMI.S0

96. Prandoni P, Piovella C, Spiezia L, Dalla F, Pesavento VR. Thrombosis and von Willebrand Factor. *Panminerva Med*. 2012;54(1):39-44. doi:10.1007/5584

97. Undas A. Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism : A New Risk. *BioMed Res Int*. 2017;2017:1-8.

98. Reddel CJ, Tan CW, Chen VM. Thrombin Generation and Cancer : Contributors and Consequences. *Cancers (Basel)*. 2019;11:1-20. doi:10.3390/cancers11010100

99. Manly DA, Boles J, Mackman N, Carolina N. Role of Tissue Factor in Venous Thrombosis. *Annu Rev Physiol*. 2011;17(73):515-525. doi:10.1146/annurev-physiol-042210-121137.Role

100. Rickles FR, Hair GA, Zeff RA, Lee E, Bona RD. Tissue factor expression in human leukocytes and tumor cells. *Thromb Haemost*. 1995;74(1):391-395.

101. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. *Clin Cancer Res*. 2007;13(10):2870-2875. doi:10.1158/1078-0432.CCR-06-2351

102. Dvorak HF, Van Dewater L, Dvorak AM, et al. Procoagulant Activity Associated with Plasma Membrane Vesicles Shed by Cultured Tumor Cells. *Cancer Res*. 1983;43(9):4434-4442.

103. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. *J Clin Oncol*. 2009;27(29):4834-4838. doi:10.1200/JCO.2009.22.6324

104. Pickering W, Gray E, Goodall AH, Ran S, Thorpe PE, Barrowcliffe TW. Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines. *J Thromb Haemost*. 2004;2(3):459-467. doi:10.1111/j.1538-7836.2004.00607.x

105. Rondon AMR, Kroone C, Kapteijn MY, Versteeg HH, Buijs JT. Role of tissue factor in tumor progression and cancer-associated thrombosis. *Semin Thromb Hemost*. 2019;45(4):396-412. doi:10.1055/s-0039-1687895

106. Indonesia PTH. PANDUAN NASIONAL TROMBOEMBOLI VENA.

107. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. *Eur J Endocrinol*. 2005;153(4):489-498. doi:10.1530/eje.1.01993

108. Adam SS, Key NS, Greenberg CS. D-dimer antigen: Current concepts and future prospects. *Blood*. 2009;113(13):2878-2887. doi:10.1182/blood-2008-06-165845

109. College B, Road K, Nabapally P-, Road APC. Study on the Levels of CRP Among the Cancer Patients Before and After Chemotherapy Treatment.

2016;(August):88-89.

110. Milroy R, Shapiro D, Shenkin A, Banham SW. Acute phase reaction during chemotherapy in small cell lung cancer. *Br J Cancer*. 1989;59(6):933-935. doi:10.1038/bjc.1989.197

111. Srimuninnimit V, Ariyapanya S, Nimmannit A, Wonglaksanapimon S, Akewanlop C, Soparattanapaisarn N. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study). *J Med Assoc Thai*. 2012;95 Suppl 2:S199-207.

112. Janelsins MC, Mustian KM, Palesh OG, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: Implications for cognitive impairment research. *Support Care Cancer*. 2012;20(4):831-839. doi:10.1007/s00520-011-1158-0

113. Sheldon J, Riches P, Gooding R, Soni N, Hobbs JR. C-reactive protein and its cytokine mediators in intensive-care patients. *Clin Chem*. 1993;39(1):147-150.

114. Gürler MY, Demir G, Moueminoglou F, Apaydin S, Lüy N. Kanser hastalari{dotless}nda kemoterapinin C-reaktif protein düzeyine ve yaşam kalitesine olan etkileri. *Turk Onkol Derg*. 2014;29(1):1-10. doi:10.5505/tjoncol.2014.655

115. Cihan YB. Significance of ABO-Rh blood groups in response and prognosis in breast cancer patients treated with radiotherapy and chemotherapy. *Asian Pacific J Cancer Prev*. 2014;15(9):4055-4060. doi:10.7314/APJCP.2014.15.9.4055

116. Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. *Crit Rev Oncol Hematol*. 2016;99:272-285. doi:10.1016/j.critrevonc.2016.01.007

117. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. *J Pathol*. 1996;179(4):358-369. doi:10.1002/(SICI)1096-9896(199608)179:4<358::AID-PATH564>3.0.CO;2-T

118. Hakomori SI. Antigen structure and genetic basis of histo-blood groups A, B and O: Their changes associated with human cancer. *Biochim Biophys Acta - Gen Subj*. 1999;1473(1):247-266. doi:10.1016/S0304-4165(99)00183-X

119. Franchini M, Mannucci PM. ABO blood group and thrombotic vascular disease. *Thromb Haemost*. 2014;112(6):1103-1109. doi:10.1160/TH14-05-0457

120. Zhou S. Is ABO blood group truly a risk factor for thrombosis and adverse outcomes? *World J Cardiol*. 2014;6(9):985. doi:10.4330/wjc.v6.i9.985

121. Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. *Onkologie*. 2008;31(12):665-670. doi:10.1159/000165054

122. Lysov Z, Swystun LL, Kuruvilla S, Arnold A, Liaw PC. Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. *Blood Coagul Fibrinolysis*. 2015;26(1):36-45. doi:10.1097/MBC.0000000000000145

123. Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. *Urology*. 2003;62(6):1078-1082. doi:10.1016/S0090-4295(03)00768-4

124. Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: A systematic review and meta-analysis. *J Clin Oncol*. 2012;30(35):4416-4426. doi:10.1200/JCO.2012.42.4358

Lampiran 1. *Informed Consent*

RSUP Dr. KARIADI Sehat Mewujudkan Sehat

REKAM MEDIS RAWAT JALAN/DARURAT/INAP RMI.00256A Hal. 1-3

Oktober 2020

PERSETUJUAN / PENOLAKAN MENJADI SUBYEK PENELITIAN	**Nama** : **No RM** : Tgl Lahir/Umur : Jenis Kelamin : Ruang : No Register : Kelas : Tgl Masuk : Nama DPJP : Nama PPJP : *(Tempelkan stiker identitas pasien jika tersedia)*

JUDUL PENELITIAN : Perbedaan Kadar CRP dan Tissue Factor pada Pasien Kanker Risiko Tinggi Trombosis Sebelum dan Sesudah Menjalani Kemoterapi

PEMBERIAN INFORMASI

Nama Peneliti : dr. Alif Adlan Zulizar

Pemberi Informasi : dr. Alif Adlan Zulizar

Penerima Informasi :

Diberikan pada tanggal / jam :

No	JENIS INFORMASI	ISI INFORMASI	Tanda (√)/paraf Penerima informasi
1	Judul Penelitian	Perbedaan Kadar CRP dan Tissue Factor pada Pasien Kanker Risiko Tinggi Trombosis Sebelum dan Sesudah Menjalani Kemoterapi	
2	Perkenalan Peneliti	Peneliti adalah Residen Ilmu Penyakit Dalam FK UNDIP / RSUP dr. Kariadi Semarang, yang akan melakukan penelitian di bagian Sub Hematologi-Onkologi Medik sebagai syarat kelulusan.	
3	Tujuan Penelitian	• Trombosis vena dalam (TVD) adalah kondisi terbentuknya bekuan darah di pembuluh darah vena dalam di pembuluh darah dari kaki atau panggul yang dapat menyebabkan rasa sakit, nyeri dan pembengkakan kaki. • Bekuan darah di pembuluh darah di kaki ini jika lepas, bisa ikut peredaran darah menuju jantung. Dari jantung menuju paru, tetapi karena pembuluh darah yang menuju paru ukuran kecil, bekuan darah bisa terhenti di pembuluh darah yang menuju paru yang di sebut emboli paru. Jika hal ini terjadi maka pasien akan mengeluh sesak napas, dan jika tidak mendapatkan pertolongan akan menyebabkan kematian. • Penelitian ini bertujuan untuk menganalisis perbedaan kadar CRP dan Tissue Factor pada pasien kanker risiko tinggi trombosis antara sebelum dan sesudah menjalani kemoterapi	
4	Manfaat Penelitian	• Penelitian ini diharapkan dapat memberikan informasi mengenai variabel-variabel yang berhubungan dengan timbulnya TEV pada pasien kanker yang berisiko tinggi trombosis di setiap siklus pemberian kemoterapi • Penelitian ini diharapkan dapat memeberikan wawasan terkait agen kemoterapi yang cenderung menyebabkan inflamasi dan trombosis pada pasien kanker, serta akan meningkatkan kewaspadaan dan mengarahkan klinisi untuk memilih terapi berdasarkan diagnosis dini, dan dapat menjadi dasar klinisi dalam keputusan pemberian tromboprofilaksis • Penelitian ini diharapkan dapat menjadi dasar untuk penelitian-penelitian lebih lanjut mengenai agen kemoterapi yang berpengaruh terhadap kejadian inflamasi dan trombosis pada pasien kanker yang menjalani kemoterapi	
5	Prosedur Penelitian	Pasien yang memenuhi kriteria inklusi sebagai calon subyek penelitian → akan diminta persetujuan untuk menjadi subyek penelitian → kemudian dilakukan pemeriksaan kadar CRP dan Tissue Factor pada saat sebelum dan sesudah kemoterapi → dilanjutkan pengolahan data dan analisis data	
6	Lama Waktu Partisipasi Subyek	Penelitian ini rencana akan dilakukan selama 3 bulan yaitu bulan Januari- maret 2022	
7	Risiko Penelitian	Tidak ada	
8	Alternatif Lain	Tidak ada	
9	Tanggung Jawab Bila Terjadi Efek Samping	Selama ini tidak ada efek samping yang berkelanjutan dari penelitian terdahulu, namun Peneliti dan RSUP Dr. Kariadi Semarang akan bertanggungjawab terhadap pasien yang menjadi subyek penelitian apabila terjadi efek samping akibat aktivitas penelitian ini	

PERSETUJUAN / PENOLAKAN MENJADI SUBYEK PENELITIAN	**Nama** : **No RM** : Tgl Lahir/Umur : Jenis Kelamin : Ruang : No Register : Kelas : Tgl Masuk : Nama DPJP : Nama PPJP : *(Tempelkan stiker identitas pasien jika tersedia)*

JUDUL PENELITIAN : Perbedaan Kadar CRP dan Tissue Factor pada Pasien Kanker Risiko Tinggi Trombosis Sebelum dan Sesudah Menjalani Kemoterapi			
10	Kerahasiaan Subyek Penelitian	Semua data penelitian termasuk didalamnya adalah identitas subyek akan dijaga kerahasiaan-nya dan menjadi tanggung jawab dari Peneliti.	
11	Kebebasan Menyetujui / Menolak	Bila pada saat pelaksanaan penelitian, subyek penelitian memutuskan untuk berhenti, maka tidak akan mempengaruhi sikap maupun pelayanan yang diberikan terhadap yang bersangkutan sebagai pasien di RSUP Dr.Kariadi Semarang	
12	Informasi Tambahan	Penelitian ini sudah mendapatkan persetujuan etik dari komisi etik penelitian RSUP Dr.Kariadi dan persetujuan pelaksanaan penelitian dari Bagian Diklit RSUP Dr.Kariadi. Jika ada hal yang masih ingin ditanyakan atau diperjelas, anda dapat langsung menanyakan kepada saya, dr. Alif Adlan Zulizar, no. HP peneliti 082220134602 atau Bagian Diklit RSUP Dr. Kariadi di nomor (024) 8413476 ext. 8033	
Dengan ini menyatakan bahwa saya telah menerangkan hal-hal di atas secara benar dan jelas dan memberikan kesempatan untuk bertanya dan/atau berdiskusi			Tanda tangan Pemberi Informasi dr. Alif Adlan Zulizar
Dengan ini menyatakan bahwa saya telah menerima informasi sebagaimana di atas yang saya beri tanda/paraf di kolom kanannya, dan telah memahaminya			Tanda tangan Penerima Informasi

Keterangan :
1. **Bila pasien tidak kompeten/tidak mau menerima informasi maka penerima informasi adalah keluarga terdekat atau wali**
2. **Isi informasi tidak boleh disingkat**

Lanjut ke halaman 3.

PERSETUJUAN MENJADI SUBYEK PENELITIAN

Yang bertanda tangan di bawah ini saya,

Nama : ……

Umur : ……tahun, laki-laki / perempuan*

Alamat : ……

dengan ini menyatakan **SETUJU** untuk menjadi responden penelitian terhadap saya / Ayah / Ibu / Anak / Keluarga saya,*

Nama : ……

Umur : ……tahun, laki-laki / perempuan*

Alamat : ……

Saya memahami tujuan dan manfaat peneltian tersebut sebagaimana telah dijelaskan seperti di atas kepada saya, termasuk risiko dan komplikasi yang mungkin timbul.

Saya juga menyadari bahwa oleh karena ilmu kedokteran bukanlah ilmu pasti, maka keberhasilantindakan kedokteran bukanlah keniscayaan, melainkan sangat bergantung kepada Tuhan Yang Maha Esa, oleh sebab itu saya membebaskan **RSUP Dr. Kariadi / dokter/Petugas lainnya** dari tanggung jawab hukum apabila risiko dan komplikasi yang tidak diharapkan benar-benar terjadi di kemudian hari.

Semarang, tanggal……..Jam……..

Yang menyatakan, Saksi I,Saksi II

(……) (……..……..) (……..……..)

PENOLAKAN MENJADI SUBYEK PENELITIAN

Yang bertanda tangan di bawah ini saya,

Nama : ……

Umur : ……tahun, laki-laki / perempuan*

Alamat : ……

dengan ini menyatakan **TIDAK SETUJU** untuk menjadi responden penelitian terhadap saya / Ayah / Ibu / Anak / Keluarga saya,*,

Nama : ……

Umur : ……tahun, laki-laki / perempuan*

Alamat : ……

Saya memahami tujuan dan manfaat penelitian tersebut sebagaimana telah dijelaskan seperti di atas kepada saya, termasuk risiko dan komplikasi yang mungkin timbul.

Saya juga menyadari bahwa oleh karena ilmu kedokteran bukanlah ilmu pasti, maka keberhasilan tindakan kedokteran bukanlah keniscayaan, melainkan sangat bergantung kepada Tuhan Yang Maha Esa, oleh sebab itu saya membebaskan **RSUP Dr. Kariadi / dokter/Petugas lainnya** dari tanggung jawab hukum apabila akibat tindakan yang tidak saya setujui terdapat risiko dan komplikasi yang tidak diharapkan benar-benar terjadi di kemudian hari.

Semarang, tanggal……..Jam……..

Yang menyatakan Saksi I,Saksi II

(……) (……..……..) (……..……..)

Lampiran 2. *Ethical Clearance*

KOMITE ETIK PENELITIAN KESEHATAN
HEALTH RESEARCH ETHICS COMMITTEE
RSUP DR. KARIADI SEMARANG
RSUP DR. KARIADI SEMARANG

RSUP Dr. KARIADI
Sehatlah Menuju Sehat

KETERANGAN LAYAK ETIK
DESCRIPTION OF ETHICAL APPROVAL
"ETHICAL *APPROVAL*"

No.1017/EC/KEPK-RSDK/2022

Protokol penelitian yang diusulkan oleh :
The research protocol proposed by

Peneliti utama : dr. Alif Adlan Zulizar
Principal In Investigator

Nama Institusi : PPDS 1 Ilmu Penyakit Dalam FK UNDIP
Name of the Institution

Dengan judul:
Title

"Perbedaan Kadar CRP dan Tissue Factor pada Pasien Kanker Risiko Tinggi Trombosis Sebelum dan Sesudah Menjalani Kemoterapi"

"Perbedaan Kadar CRP dan Tissue Factor pada Pasien Kanker Risiko Tinggi Trombosis Sebelum dan Sesudah Menjalani Kemoterapi"

Dinyatakan layak etik sesuai 7 (tujuh) Standar WHO 2011, yaitu 1) Nilai Sosial, 2) Nilai Ilmiah, 3) Pemerataan Beban dan Manfaat, 4) Risiko, 5) Bujukan/Eksploitasi, 6) Kerahasiaan dan Privacy, dan 7) Persetujuan Setelah Penjelasan, yang merujuk pada Pedoman CIOMS 2016. Hal ini seperti yang ditunjukkan oleh terpenuhinya indicator setiap standar.

Declared to be ethically appropriate in accordance to 7 (seven) WHO 2011 Standards, *1) Social Values, 2) Scientific Values, 3) Equitable Assessment and Benefits, 4) Risks, 5) Persuasion/Exploitation, 6) Confidentiality and Privacy, and 7) Informed Concent, referring to the 2016 CIOMS Guidelines. This is as indicated by the fulfillment of the indicators of each standard.*

Pernyataan Laik Etik ini berlaku selama kurun waktu tanggal 20 Januari 2022 sampai dengan tanggal 20 Januari 2023.

This declaration of ethics applies during the period January 20, 2022 until January 20, 2023.

January 20, 2022
Professor and Chairperson,

Dr. dr. M. Sofyan Harahap, SpAn.,KNA

Lampiran 3. Hasil Uji Analisis Statistik

Jenis Kelamin					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	35	47,9	47,9	47,9
	Perempuan	38	52,1	52,1	100,0
	Total	73	100,0	100,0	

Golongan Darah					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	A	8	11,0	11,0	11,0
	AB	7	9,6	9,6	20,5
	B	38	52,1	52,1	72,6
	O	20	27,4	27,4	100,0
	Total	73	100,0	100,0	

ECOG-PS					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	0	36	49,3	49,3	49,3
	1	30	41,1	41,1	90,4
	2	6	8,2	8,2	98,6
	3	1	1,4	1,4	100,0
	Total	73	100,0	100,0	

Diagnosis					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ca Colorectal	27	37,0	37,0	37,0
	Lainnya	9	12,3	12,3	49,3
	Ca Paru	11	15,1	15,1	64,4
	Ca Pankreas	7	9,6	9,6	74,0
	LMNH	6	8,2	8,2	82,2
	Ca Buli	3	4,1	4,1	86,3
	Ca Gaster	2	2,7	2,7	89,0
	Ca Mammae	4	5,5	5,5	94,5

	Ca Renal	2	2,7	2,7	97,3
	LMH	2	2,7	2,7	100,0
	Total	73	100,0	100,0	

Regimen Kemoterapi

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Cisplatin-based	29	39,7	39,7	39,7
	Fluorouracil-based	35	47,9	47,9	87,7
	Steroid based	5	6,8	6,8	94,5
	Antrasiklin based	4	5,5	5,5	100,0
	Total	73	100,0	100,0	

Staging Tumor

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	I	5	6,8	6,8	6,8
	II	7	9,6	9,6	16,4
	III	21	28,8	28,8	45,2
	IV	40	54,8	54,8	100,0
	Total	73	100,0	100,0	

Risiko Kanker

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Risiko Tinggi	36	49,3	49,3	49,3
	Risiko Rendah	37	50,7	50,7	100,0
	Total	73	100,0	100,0	

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
CRP H-1	,220	73	,000	,777	73	,000
CRP H+1	,201	73	,000	,789	73	,000

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]	Shapiro-Wilk

	Statistic	df	Sig.	Statistic	df	Sig.
TF H-1	,253	73	,000	,685	73	,000
TF H+1	,230	73	,000	,765	73	,000
a. Lilliefors Significance Correction						

NPar Tests

Notes		
Output Created		
Comments		
Input	Data	
	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	73
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each test are based on all cases with valid data for the variable(s) used in that test.
Syntax		NPAR TESTS /WILCOXON=CRP_H_1 WITH CRP_H1 (PAIRED) /MISSING ANALYSIS.
Resources	Processor Time	00:00:00,02
	Elapsed Time	00:00:00,11
	Number of Cases Allowed[a]	449389
a. Based on availability of workspace memory.		

Wilcoxon Signed Ranks Test

Ranks				
		N	Mean Rank	Sum of Ranks
CRP H+1 - CRP H-1	Negative Ranks	49[a]	36,82	1804,00
	Positive Ranks	23[b]	35,83	824,00
	Ties	1[c]		
	Total	73		
a. CRP H+1 < CRP H-1				

b. CRP H+1 > CRP H-1
c. CRP H+1 = CRP H-1

Test Statistics[a]	
	CRP H+1 - CRP H-1
Z	-2,750[b]
Asymp. Sig. (2-tailed)	,006
a. Wilcoxon Signed Ranks Test	
b. Based on positive ranks.	

NPar Tests

Notes		
Output Created		08-JUN-2022 22:17:09
Comments		
Input	Data	
	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	73
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics for each test are based on all cases with valid data for the variable(s) used in that test.
Syntax		NPAR TESTS /WILCOXON=TF_H_1 WITH TF_H1 (PAIRED) /MISSING ANALYSIS.
Resources	Processor Time	00:00:00,00
	Elapsed Time	00:00:00,02
	Number of Cases Allowed[a]	449389
a. Based on availability of workspace memory.		

Wilcoxon Signed Ranks Test

Ranks				
		N	Mean Rank	Sum of Ranks
TF H+1 - TF H-1	Negative Ranks	34[a]	37,53	1276,00
	Positive Ranks	39[b]	36,54	1425,00
	Ties	0[c]		
	Total	73		
a. TF H+1 < TF H-1				
b. TF H+1 > TF H-1				
c. TF H+1 = TF H-1				

Test Statistics[a]	
	TF H+1 - TF H-1
Z	-,410[b]
Asymp. Sig. (2-tailed)	,682
a. Wilcoxon Signed Ranks Test	
b. Based on negative ranks.	

Kruskal-Wallis Test

Ranks			
	Golongan Darah	N	Mean Rank
Penurunan CRP	A	8	37,38
	AB	7	41,00
	B	38	36,61
	O	20	36,20
	Total	73	

Test Statistics[a,b]	
	Penurunan CRP
Kruskal-Wallis H	,293
df	3
Asymp. Sig.	,961
a. Kruskal Wallis Test	
b. Grouping Variable: Golongan Darah	

Mann-Whitney Test

Ranks				
	Diagnosis	N	Mean Rank	Sum of Ranks
Penurunan CRP	Ca Colorectal	27	18,91	510,50
	Lainnya	9	17,28	155,50
	Total	36		

Test Statistics[a]

	Penurunan CRP
Mann-Whitney U	110,500
Wilcoxon W	155,500
Z	-,402
Asymp. Sig. (2-tailed)	,688
Exact Sig. [2*(1-tailed Sig.)]	,693[b]
a. Grouping Variable: Diagnosis	
b. Not corrected for ties.	

Kruskal-Wallis Test

Ranks			
	Staging Tumor	N	Mean Rank
Penurunan CRP	I	5	26,40
	II	7	24,86
	III	21	36,98
	IV	40	40,46
	Total	73	
CRP H-1	I	5	27,40
	II	7	16,71
	III	21	36,14
	IV	40	42,20
	Total	73	
CRP H+1	I	5	29,60
	II	7	18,14
	III	21	34,67
	IV	40	42,45
	Total	73	

Test Statistics[a,b]			
	Penurunan CRP	CRP H-1	CRP H+1
Kruskal-Wallis H	4,606	9,860	9,031
df	3	3	3
Asymp. Sig.	,203	,020	,029
a. Kruskal Wallis Test			
b. Grouping Variable: Staging Tumor			

Kruskal-Wallis Test

Ranks			
	Regimen Kemoterapi	N	Mean Rank
Penurunan CRP	Cisplatin-based	29	39,57
	Fluorouracil-based	35	35,07
	Steroid based	5	24,60
	Antrasiklin based	4	50,75
	Total	73	
CRP H-1	Cisplatin-based	29	43,66
	Fluorouracil-based	35	31,26
	Steroid based	5	31,40
	Antrasiklin based	4	46,00
	Total	73	
CRP H+1	Cisplatin-based	29	42,76
	Fluorouracil-based	35	31,09
	Steroid based	5	40,80
	Antrasiklin based	4	42,25
	Total	73	

Test Statistics[a,b]			
	Penurunan CRP	CRP H-1	CRP H+1
Kruskal-Wallis H	4,102	6,486	5,261
df	3	3	3
Asymp. Sig.	,251	,090	,154
a. Kruskal Wallis Test			
b. Grouping Variable: Regimen Kemoterapi			

Kruskal-Wallis Test

Ranks			
	Regimen Kemoterapi	N	Mean Rank
TF H-1	Cisplatin-based	29	35,26
	Fluorouracil-based	35	42,49

	Steroid based	5	20,50
	Antrasiklin based	4	22,25
	Total	73	
TF H+1	Cisplatin-based	29	41,19
	Fluorouracil-based	35	34,23
	Steroid based	5	35,80
	Antrasiklin based	4	32,38
	Total	73	
Peningkatan Tissue Factor	Cisplatin-based	29	40,55
	Fluorouracil-based	35	31,60
	Steroid based	5	50,20
	Antrasiklin based	4	42,00
	Total	73	

Test Statistics[a,b]

	TF H-1	TF H+1	Peningkatan Tissue Factor
Kruskal-Wallis H	7,493	1,934	5,237
df	3	3	3
Asymp. Sig.	,058	,586	,155

a. Kruskal Wallis Test

b. Grouping Variable: Regimen Kemoterapi

Golongan Darah

Case Processing Summary

	Golongan Darah	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Penurunan CRP	A	8	100,0%	0	0,0%	8	100,0%
	AB	7	100,0%	0	0,0%	7	100,0%
	B	38	100,0%	0	0,0%	38	100,0%
	O	20	100,0%	0	0,0%	20	100,0%

Descriptives

	Jenis Kelamin			Statistic	Std. Error
Penurunan CRP	Laki-laki	Mean		,8483	,55576
		95% Confidence Interval for Mean	Lower Bound	-,2811	
			Upper Bound	1,9777	
		5% Trimmed Mean		,7648	

		Median		,8100	
		Variance		10,810	
		Std. Deviation		3,28791	
		Minimum		-8,53	
		Maximum		12,65	
		Range		21,18	
		Interquartile Range		2,41	
		Skewness		,727	,398
		Kurtosis		5,596	,778
	Peremp	Mean		,9024	,52004
	uan	95% Confidence Interval for	Lower Bound	-,1513	
		Mean	Upper Bound	1,9561	
		5% Trimmed Mean		,6718	
		Median		,2650	
		Variance		10,277	
		Std. Deviation		3,20573	
		Minimum		-6,36	
		Maximum		11,04	
		Range		17,40	
		Interquartile Range		2,22	
		Skewness		1,510	,383
		Kurtosis		4,412	,750

Descriptives

	Jenis Kelamin			Statistic	Std. Error
Peningkata	Laki-laki	Mean		,4743	18,68215
n Tissue		95% Confidence Interval for	Lower Bound	-37,4924	
Factor		Mean	Upper Bound	38,4410	
		5% Trimmed Mean		-6,6706	
		Median		-2,4000	
		Variance		12215,802	
		Std. Deviation		110,52512	
		Minimum		-200,80	
		Maximum		382,30	
		Range		583,10	
		Interquartile Range		103,30	
		Skewness		1,228	,398
		Kurtosis		3,280	,778
	Peremp	Mean		31,0000	20,22323

	uan	95% Confidence Interval for Mean	Lower Bound	-9,9762	
			Upper Bound	71,9762	
		5% Trimmed Mean		23,3421	
		Median		5,0500	
		Variance		15541,206	
		Std. Deviation		124,66438	
		Minimum		-227,30	
		Maximum		390,10	
		Range		617,40	
		Interquartile Range		96,13	
		Skewness		1,229	,383
		Kurtosis		2,287	,750

Descriptives

	Golongan Darah			Statistic	Std. Error
Penurunan CRP	A	Mean		,6913	,43280
		95% Confidence Interval for Mean	Lower Bound	-,3321	
			Upper Bound	1,7146	
		5% Trimmed Mean		,6792	
		Median		,2300	
		Variance		1,498	
		Std. Deviation		1,22413	
		Minimum		-,97	
		Maximum		2,57	
		Range		3,54	
		Interquartile Range		2,07	
		Skewness		,442	,752
		Kurtosis		-1,032	1,481
	AB	Mean		1,0943	,60789
		95% Confidence Interval for Mean	Lower Bound	-,3932	
			Upper Bound	2,5817	
		5% Trimmed Mean		,9748	
		Median		,2500	
		Variance		2,587	
		Std. Deviation		1,60833	
		Minimum		-,10	
		Maximum		4,44	
		Range		4,54	
		Interquartile Range		1,60	

		Skewness		1,893	,794
		Kurtosis		3,637	1,587
	B	Mean		,7874	,62285
		95% Confidence Interval for Mean	Lower Bound	-,4746	
			Upper Bound	2,0494	
		5% Trimmed Mean		,6362	
		Median		,2800	
		Variance		14,742	
		Std. Deviation		3,83949	
		Minimum		-8,53	
		Maximum		12,65	
		Range		21,18	
		Interquartile Range		2,90	
		Skewness		,774	,383
		Kurtosis		3,106	,750
	O	Mean		1,0435	,67847
		95% Confidence Interval for Mean	Lower Bound	-,3766	
			Upper Bound	2,4636	
		5% Trimmed Mean		,7122	
		Median		,6700	
		Variance		9,207	
		Std. Deviation		3,03423	
		Minimum		-2,99	
		Maximum		11,04	
		Range		14,03	
		Interquartile Range		2,26	
		Skewness		2,198	,512
		Kurtosis		6,039	,992

Descriptives

	Staging Tumor			Statistic	Std. Error
Penurunan CRP	I	Mean		-,0640	,31093
		95% Confidence Interval for Mean	Lower Bound	-,9273	
			Upper Bound	,7993	
		5% Trimmed Mean		-,0656	
		Median		,0800	
		Variance		,483	
		Std. Deviation		,69526	
		Minimum		-,97	

		Maximum		,87	
		Range		1,84	
		Interquartile Range		1,24	
		Skewness		,025	,913
		Kurtosis		-,161	2,000
	II	Mean		-,4300	,51161
		95% Confidence Interval for Mean	Lower Bound	-1,6819	
			Upper Bound	,8219	
		5% Trimmed Mean		-,2983	
		Median		,0200	
		Variance		1,832	
		Std. Deviation		1,35360	
		Minimum		-3,48	
		Maximum		,25	
		Range		3,73	
		Interquartile Range		,36	
		Skewness		-2,575	,794
		Kurtosis		6,715	1,587
	III	Mean		,4543	,57330
		95% Confidence Interval for Mean	Lower Bound	-,7416	
			Upper Bound	1,6502	
		5% Trimmed Mean		,6065	
		Median		,3700	
		Variance		6,902	
		Std. Deviation		2,62721	
		Minimum		-8,53	
		Maximum		6,49	
		Range		15,02	
		Interquartile Range		1,55	
		Skewness		-1,458	,501
		Kurtosis		7,741	,972
	IV	Mean		1,4442	,60121
		95% Confidence Interval for Mean	Lower Bound	,2282	
			Upper Bound	2,6603	
		5% Trimmed Mean		1,2489	
		Median		1,2450	
		Variance		14,458	
		Std. Deviation		3,80237	
		Minimum		-6,36	

		Maximum	12,65	
		Range	19,01	
		Interquartile Range	3,37	
		Skewness	1,155	,374
		Kurtosis	2,398	,733

Descriptives

	Risiko Kanker			Statistic	Std. Error
Peningkatan Tissue Factor	Risiko Tinggi	Mean		12,8722	21,10456
		95% Confidence Interval for Mean	Lower Bound	-29,9723	
			Upper Bound	55,7167	
		5% Trimmed Mean		7,5321	
		Median		5,3000	
		Variance		16034,483	
		Std. Deviation		126,62734	
		Minimum		-227,30	
		Maximum		390,10	
		Range		617,40	
		Interquartile Range		76,18	
		Skewness		,753	,393
		Kurtosis		1,477	,768
	Risiko Menengah	Mean		19,7622	18,28342
		95% Confidence Interval for Mean	Lower Bound	-17,3183	
			Upper Bound	56,8427	
		5% Trimmed Mean		6,5308	
		Median		-2,1000	
		Variance		12368,494	
		Std. Deviation		111,21373	
		Minimum		-108,70	
		Maximum		382,30	
		Range		491,00	
		Interquartile Range		86,20	
		Skewness		1,983	,388
		Kurtosis		4,517	,759

Descriptives

	Regimen Kemoterapi		Statistic	Std. Error
Penurunan	Cisplatin-	Mean	,9862	,62419

CRP	based	95% Confidence Interval for Mean	Lower Bound	-,2924	
			Upper Bound	2,2648	
		5% Trimmed Mean		,8708	
		Median		,8900	
		Variance		11,299	
		Std. Deviation		3,36139	
		Minimum		-6,36	
		Maximum		11,04	
		Range		17,40	
		Interquartile Range		1,98	
		Skewness		,713	,434
		Kurtosis		2,598	,845
	Fluorouracil-based	Mean		,5429	,46798
		95% Confidence Interval for Mean	Lower Bound	-,4082	
			Upper Bound	1,4939	
		5% Trimmed Mean		,5088	
		Median		,2500	
		Variance		7,665	
		Std. Deviation		2,76860	
		Minimum		-8,53	
		Maximum		10,85	
		Range		19,38	
		Interquartile Range		1,86	
		Skewness		,543	,398
		Kurtosis		7,797	,778
	Steroid based	Mean		1,7740	2,72202
		95% Confidence Interval for Mean	Lower Bound	-5,7835	
			Upper Bound	9,3315	
		5% Trimmed Mean		1,3344	
		Median		-,9700	
		Variance		37,047	
		Std. Deviation		6,08661	
		Minimum		-1,19	
		Maximum		12,65	
		Range		13,84	
		Interquartile Range		7,26	
		Skewness		2,224	,913
		Kurtosis		4,955	2,000
	Antrasiklin	Mean		1,8775	,93052

	based	95% Confidence Interval for Mean	Lower Bound	-1,0838	
			Upper Bound	4,8388	
		5% Trimmed Mean		1,8239	
		Median		1,3950	
		Variance		3,463	
		Std. Deviation		1,86105	
		Minimum		,28	
		Maximum		4,44	
		Range		4,16	
		Interquartile Range		3,44	
		Skewness		1,175	1,014
		Kurtosis		,725	2,619

Descriptives

	Regimen Kemoterapi			Statistic	Std. Error
Peningkatan Tissue Factor	Cisplatin-based	Mean		27,7276	23,19889
		95% Confidence Interval for Mean	Lower Bound	-19,7932	
			Upper Bound	75,2484	
		5% Trimmed Mean		22,8623	
		Median		9,4000	
		Variance		15607,471	
		Std. Deviation		124,92986	
		Minimum		-227,30	
		Maximum		379,30	
		Range		606,60	
		Interquartile Range		139,50	
		Skewness		,697	,434
		Kurtosis		1,462	,845
	Fluorouracil-based	Mean		-,9543	20,42985
		95% Confidence Interval for Mean	Lower Bound	-42,4727	
			Upper Bound	40,5642	
		5% Trimmed Mean		-12,6937	
		Median		-14,2000	
		Variance		14608,252	
		Std. Deviation		120,86460	
		Minimum		-200,80	
		Maximum		390,10	
		Range		590,90	
		Interquartile Range		87,80	

		Skewness		1,901	,398
		Kurtosis		4,816	,778
	Steroid based	Mean		76,4600	44,78869
		95% Confidence Interval for Mean	Lower Bound	-47,8933	
			Upper Bound	200,8133	
		5% Trimmed Mean		73,2833	
		Median		9,6000	
		Variance		10030,133	
		Std. Deviation		100,15055	
		Minimum		1,40	
		Maximum		208,70	
		Range		207,30	
		Interquartile Range		182,65	
		Skewness		,735	,913
		Kurtosis		-2,568	2,000
	Antrasiklin based	Mean		10,4000	9,51569
		95% Confidence Interval for Mean	Lower Bound	-19,8832	
			Upper Bound	40,6832	
		5% Trimmed Mean		10,0500	
		Median		7,2500	
		Variance		362,193	
		Std. Deviation		19,03138	
		Minimum		-9,30	
		Maximum		36,40	
		Range		45,70	
		Interquartile Range		34,85	
		Skewness		,952	1,014
		Kurtosis		1,948	2,619

Penurunan CRP



Staging Tumor

Case Processing Summary							
		Cases					
		Valid		Missing		Total	
	Staging Tumor	N	Percent	N	Percent	N	Percent
Penurunan CRP	I	5	100,0%	0	0,0%	5	100,0%
	II	7	100,0%	0	0,0%	7	100,0%
	III	21	100,0%	0	0,0%	21	100,0%
	IV	40	100,0%	0	0,0%	40	100,0%

Penurunan CRP



Risiko Kanker

Case Processing Summary							
		Cases					
		Valid		Missing		Total	
	Risiko Kanker	N	Percent	N	Percent	N	Percent
Penurunan CRP	Risiko Tinggi	36	100,0%	0	0,0%	36	100,0%
	Risiko Rendah	37	100,0%	0	0,0%	37	100,0%

Penurunan CRP



Regimen Kemoterapi

Case Processing Summary

		Cases					
		Valid		Missing		Total	
	Regimen Kemoterapi	N	Percent	N	Percent	N	Percent
Peningkatan Tissue Factor	Cisplatin-based	29	100,0%	0	0,0%	29	100,0%
	Fluorouracil-based	35	100,0%	0	0,0%	35	100,0%
	Steroid based	5	100,0%	0	0,0%	5	100,0%
	Antrasiklin based	4	100,0%	0	0,0%	4	100,0%

Peningkatan Tissue Factor



Regimen Kemoterapi

Case Processing Summary							
		Cases					
		Valid		Missing		Total	
	Regimen Kemoterapi	N	Percent	N	Percent	N	Percent
Penurunan CRP	Cisplatin-based	29	100,0%	0	0,0%	29	100,0%
	Fluorouracil-based	35	100,0%	0	0,0%	35	100,0%
	Steroid based	5	100,0%	0	0,0%	5	100,0%
	Antrasiklin based	4	100,0%	0	0,0%	4	100,0%

Penurunan CRP



Descriptives					
	Golongan Darah			Statistic	Std. Error
Peningkatan Tissue Factor	A	Mean		25,6750	28,22575
		95% Confidence Interval for Mean	Lower Bound	-41,0683	
			Upper Bound	92,4183	
		5% Trimmed Mean		23,5222	
		Median		5,3000	
		Variance		6373,542	
		Std. Deviation		79,83447	
		Minimum		-70,20	
		Maximum		160,30	
		Range		230,50	
		Interquartile Range		128,53	
		Skewness		,975	,752

		Kurtosis		-,129	1,481
	AB	Mean		-10,9714	43,70526
		95% Confidence Interval for Mean	Lower Bound	-117,9144	
			Upper Bound	95,9715	
		5% Trimmed Mean		-8,8627	
		Median		2,5000	
		Variance		13371,049	
		Std. Deviation		115,63325	
		Minimum		-227,30	
		Maximum		167,40	
		Range		394,70	
		Interquartile Range		41,80	
		Skewness		-,667	,794
		Kurtosis		2,961	1,587
	B	Mean		19,5263	21,48900
		95% Confidence Interval for Mean	Lower Bound	-24,0145	
			Upper Bound	63,0672	
		5% Trimmed Mean		10,0845	
		Median		-3,7500	
		Variance		17547,538	
		Std. Deviation		132,46712	
		Minimum		-200,80	
		Maximum		390,10	
		Range		590,90	
		Interquartile Range		88,50	
		Skewness		1,245	,383
		Kurtosis		1,669	,750
	O	Mean		16,2000	24,43758
		95% Confidence Interval for Mean	Lower Bound	-34,9484	
			Upper Bound	67,3484	
		5% Trimmed Mean		3,7889	
		Median		15,4000	
		Variance		11943,906	
		Std. Deviation		109,28818	
		Minimum		-126,50	
		Maximum		382,30	
		Range		508,80	
		Interquartile Range		111,28	
		Skewness		1,876	,512

		Kurtosis	6,165	,992

Test Statistics[a,b]	
	Peningkatan Tissue Factor
Kruskal-Wallis H	,826
df	3
Asymp. Sig.	,843
a. Kruskal Wallis Test	
b. Grouping Variable: Golongan Darah	

Descriptives					
	Staging Tumor			Statistic	Std. Error
Peningkatan Tissue Factor	I	Mean		27,4400	37,39921
		95% Confidence Interval for Mean	Lower Bound	-76,3968	
			Upper Bound	131,2768	
		5% Trimmed Mean		25,4833	
		Median		17,0000	
		Variance		6993,503	
		Std. Deviation		83,62717	
		Minimum		-70,20	
		Maximum		160,30	
		Range		230,50	
		Interquartile Range		128,90	
		Skewness		,994	,913
		Kurtosis		2,298	2,000
	II	Mean		69,0571	35,26376
		95% Confidence Interval for Mean	Lower Bound	-17,2302	
			Upper Bound	155,3445	
		5% Trimmed Mean		67,6635	
		Median		25,7000	
		Variance		8704,730	
		Std. Deviation		93,29914	
		Minimum		-25,30	

		Maximum		188,50	
		Range		213,80	
		Interquartile Range		187,40	
		Skewness		,332	,794
		Kurtosis		-2,386	1,587
	III	Mean		-22,2762	17,71224
		95% Confidence Interval for Mean	Lower Bound	-59,2233	
			Upper Bound	14,6709	
		5% Trimmed Mean		-20,0098	
		Median		2,5000	
		Variance		6588,193	
		Std. Deviation		81,16768	
		Minimum		-227,30	
		Maximum		141,90	
		Range		369,20	
		Interquartile Range		109,90	
		Skewness		-,619	,501
		Kurtosis		1,044	,972
	IV	Mean		26,0450	21,78302
		95% Confidence Interval for Mean	Lower Bound	-18,0153	
			Upper Bound	70,1053	
		5% Trimmed Mean		17,1833	
		Median		-1,7500	
		Variance		18980,002	
		Std. Deviation		137,76793	
		Minimum		-200,80	
		Maximum		390,10	
		Range		590,90	
		Interquartile Range		81,40	
		Skewness		1,344	,374
		Kurtosis		1,757	,733

Test Statistics[a,b]	
	Peningkatan Tissue Factor
Kruskal-Wallis H	3,372
df	3
Asymp. Sig.	,338
a. Kruskal Wallis Test	
b. Grouping Variable: Staging Tumor	

Descriptives					
	Risiko Kanker			Statistic	Std. Error
Peningkatan Tissue Factor	Risiko Tinggi	Mean		12,8722	21,10456
		95% Confidence Interval for Mean	Lower Bound	-29,9723	
			Upper Bound	55,7167	
		5% Trimmed Mean		7,5321	
		Median		5,3000	
		Variance		16034,483	
		Std. Deviation		126,62734	
		Minimum		-227,30	
		Maximum		390,10	
		Range		617,40	
		Interquartile Range		76,18	
		Skewness		,753	,393
		Kurtosis		1,477	,768
	Risiko Rendah	Mean		19,7622	18,28342
		95% Confidence Interval for Mean	Lower Bound	-17,3183	
			Upper Bound	56,8427	
		5% Trimmed Mean		6,5308	
		Median		-2,1000	
		Variance		12368,494	
		Std. Deviation		111,21373	
		Minimum		-108,70	
		Maximum		382,30	
		Range		491,00	
		Interquartile Range		86,20	
		Skewness		1,983	,388
		Kurtosis		4,517	,759

Test Statistics[a,b]	
	Peningkatan Tissue Factor
Kruskal-Wallis H	,064
df	1
Asymp. Sig.	,800
a. Kruskal Wallis Test	
b. Grouping Variable: Risiko Kanker	

Regimen Kemoterapi

Case Processing Summary							
		Cases					
		Valid		Missing		Total	
	Regimen Kemoterapi	N	Percent	N	Percent	N	Percent
Peningkatan Tissue Factor	Cisplatin-based	29	100,0%	0	0,0%	29	100,0%
	Fluorouracil-based	35	100,0%	0	0,0%	35	100,0%
	Steroid based	5	100,0%	0	0,0%	5	100,0%
	Antrasiklin based	4	100,0%	0	0,0%	4	100,0%

Peningkatan Tissue Factor



Regimen Kemoterapi

Case Processing Summary				
		Cases		
	Regimen Kemoterapi	Valid	Missing	Total

		N	Percent	N	Percent	N	Percent
Penurunan CRP	Cisplatin-based	29	100,0%	0	0,0%	29	100,0%
	Fluorouracil-based	35	100,0%	0	0,0%	35	100,0%
	Steroid based	5	100,0%	0	0,0%	5	100,0%
	Antrasiklin based	4	100,0%	0	0,0%	4	100,0%

Penurunan CRP